Clinical Trials
69 trialsMorning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
Sichuan University
USZ-STRIKE
ETOP IBCSG Partners Foundation
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure Ltd.
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
Peking University People's Hospital
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
JACKPOT38
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
SARCO-CTI
Ankara Etlik City Hospital
Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
SKY
Sichuan University
Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
Anhui Provincial Hospital
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
Shenyang Sunshine Pharmaceutical Co., LTD.
Dupilumab_Metastatic NSCLC
Icahn School of Medicine at Mount Sinai
A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PRIMM
University Medical Centre Maribor
Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
BioAtla, Inc.
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Hutchmed
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
The First Affiliated Hospital of Zhengzhou University
A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
Xinqiao Hospital of Chongqing
An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment
Xinqiao Hospital of Chongqing
Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
Xinqiao Hospital of Chongqing
Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
PROPHET
Sun Yat-sen University
Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer
Shanghai Chest Hospital
NMN
Sichuan University
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
CCICC-002b
Tianjin Medical University Cancer Institute and Hospital
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
Peking University Cancer Hospital & Institute
CLASSIC5
Hunan Province Tumor Hospital
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
BioAtla, Inc.
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
The First Affiliated Hospital of Nanchang University
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
The First Affiliated Hospital of Nanchang University
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
The First Affiliated Hospital of Nanchang University
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
The First Affiliated Hospital of Nanchang University
Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients
Seoul National University
Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
Shanghai Chest Hospital
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
Peking Union Medical College Hospital
ATPase
Hunan Province Tumor Hospital
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
CONFIRM
Hunan Province Tumor Hospital
CREATE
Hunan Province Tumor Hospital
The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
CHEERS
University Hospital, Ghent
Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure
The Central Hospital of Lishui City
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center